Medical Centre Hungarian Defence Forces

The Medical Centre Hungarian Defence Forces in Budapest is conducting research focused on advanced cancer therapies, aiming to improve survival and quality of life for patients with hard‑to‑treat tumors. Trials explore novel targeted agents, immunotherapy combinations, and biomarker‑driven approaches across several tumor types.

• Targeted therapy for gastrointestinal stromal tumors
• Immunotherapy plus hormonal treatment for metastatic prostate cancer
• HER2‑directed treatment strategies for urothelial carcinoma
• Neoadjuvant immunotherapy for resectable head and neck squamous cell carcinoma
• Innovative agents for advanced solid tumors

The department supports 12 active clinical trials with 9 investigators, reflecting a strong commitment to oncology research.

Research at the centre addresses disorders of the gastrointestinal tract, seeking safer and more effective treatments for chronic inflammatory conditions and tumor‑related complications. Studies evaluate oral and injectable therapies that aim to reduce disease activity and prevent progression.

• New oral agents for ulcerative colitis
• Molecularly driven therapies for gastrointestinal stromal tumors
• Biomarker‑guided strategies in digestive cancers
• Combination regimens to improve mucosal healing
• Patient‑reported outcome measures in chronic gut diseases

The site’s multidisciplinary team integrates gastroenterology expertise to advance therapeutic options for patients across the digestive system.

The department’s ophthalmology program evaluates cutting‑edge ocular therapies, with the goal of preserving vision and reducing retinal damage. Trials test gene‑based treatments and anti‑vascular agents to address age‑related degeneration and vascular complications.

• Intravitreal gene therapy for geographic atrophy
• Anti‑VEGF strategies for macular edema secondary to retinal vein occlusion
• Long‑acting delivery systems for retinal diseases
• Comparative studies of dosing intervals for ocular injections
• Safety assessments of novel ocular biologics

These studies contribute to the development of treatments that can halt or reverse vision loss in patients with serious eye conditions.

Investigations into joint and connective‑tissue disorders focus on biologic therapies that modulate immune pathways, aiming to reduce inflammation and improve functional outcomes for people with arthritis.

• Biologic modulation of joint inflammation in psoriatic arthritis
• Dose‑optimization studies for new anti‑inflammatory agents
• Combination approaches with existing disease‑modifying drugs
• Imaging biomarkers to track treatment response
• Quality‑of‑life assessments in musculoskeletal trials

The research supports the development of therapies that can provide lasting relief for patients with chronic musculoskeletal pain.

Although fewer studies are listed in this area, the centre maintains capacity to evaluate antimicrobial and antifungal agents, emphasizing safety and efficacy in vulnerable patient groups.

• Exploratory trials of new antibacterial compounds
• Safety profiling of antifungal therapies in immunocompromised patients
• Pharmacokinetic studies of novel infection‑control drugs
• Diagnostic biomarker validation for resistant infections
• Integrated stewardship programs within the hospital setting

Ongoing collaboration with infectious‑disease specialists ensures readiness to launch additional studies as new agents become available.